YH003
Drug timelines are a Plus or Pro feature.
4 regulatory and trial events tracked for YH003, covering 2022-12-12 to 2025-01-06. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Assess YH003 in Combination with Pebolizumab and Albumin Paclitaxel Injection in Subjects with Unresectable/metastatic Mucosal Melanoma [Phase 2]